Trepmac 90mg Tablet is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Brigatinib is used to treat a specific type of non-small cell lung cancer (NSCLC) that has metastasized to other parts of the body. It belongs to a class of medications called kinase inhibitors, working by blocking the action of an abnormal protein that signals cancer cells to multiply, thus slowing or halting the spread of cancer cells.
Before taking brigatinib, inform your healthcare provider about:
Brigatinib may interfere with hormonal contraceptives. Use non-hormonal birth control methods during treatment. Females should use non-hormonal contraception during treatment and for 4 months after the final dose. Males and their partners should use birth control during treatment and for 3 months after the final dose.
Common side effects may include nausea, diarrhea, vomiting, tiredness, rash, headache, numbness or pain in hands or feet, joint or back pain, loss of appetite, and difficulty sleeping. Serious side effects may include difficulty breathing, chest pain, persistent cough, fever, severe headache, blurred vision, extreme thirst, frequent urination, muscle pain or weakness, and slow or irregular heartbeat.
Non-Small Cell Lung Cancer
Increased AST, hyperglycemia, increased ALT, nausea, fatigue, headache, increased CPK, increased amylase, dyspnea, vomiting, anemia, decreased appetite, prolonged aPTT, increased lipase, diarrhea, constipation, lymphopenia, cough, abdominal pain, increased alkaline phosphatase, decreased phosphorus, rash, pyrexia, arthralgia, peripheral neuropathy, muscle spasms, hypertension, pain in extremity, insomnia.
Non-small cell Lung Cancer (NSCLC) is indicated for anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC in patients who have progressed on or are intolerant to crizotinib.
Absorption:
Distribution:
Elimination:
Metabolism:
Excretion:
Adult Dose:
Hepatic Impairment:
Renal Dose:
Hypersensitivity to Brigatinib or any other components.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.